Search

Your search keyword '"Munir, Kashif M"' showing total 209 results
Start Over Author "Munir, Kashif M"
209 results on '"Munir, Kashif M"'

19. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.

Author

Park, Jeayoung, Ntelis, Spyridon, Yunasan, Elvina, Downton, Katherine D, Yip, Terry Cheuk-Fung, Munir, Kashif M, and Haq, Nowreen

Subjects
GLUCAGON-like peptide 1, TYPE 1 diabetes, TREATMENT of diabetes
Abstract

Context Concomitant obesity is common among patients with type 1 diabetes mellitus (T1DM), yet adjunctive therapy options are scarce. Objective We assess the efficacy and adverse outcomes of glucagon-like peptide 1 (GLP-1) analogues when used as adjunctive therapy for T1DM. Method PubMed, EMBASE, Cochrane Central, and Scopus databases were searched for randomized controlled trials up to December 2022. Efficacy outcomes were A1c level, body weight, and total daily insulin (TDI) after ≥12 weeks of GLP-1 therapy. We also assessed 12 different adverse outcomes. Subgroup analysis was done for newly diagnosed or C-peptide positive (C-pos) patients. We report the certainty of evidence based on the GRADE assessment tool. Results A total of 24 studies using 4 different GLP-1 analogues with a total of 3377 patients were included. Liraglutide had the most substantial evidence with effect sizes on A1c (−0.09%/mg), weight (−2.2 kg/mg), and TDI (−4.32 IU/mg). Liraglutide dose was the greatest predictor of greater average weight loss and TDI decrease but was associated with higher odds of nausea (OR 6.5; 95% CI, 5.0-8.4) and ketosis (OR 1.8; 95% CI, 1.1-2.8). Odds of severe (OR 0.67; 95% CI, 0.43-1.04) or symptomatic hypoglycemia (OR 0.89; 95% CI, 0.53-1.51) were not significantly elevated. Among C-pos patients, greater A1c decrease (−0.51% vs −0.28%) but similar weight loss and TDI were seen. Effect sizes for exenatide were similar, but studies had higher risk of bias and safety data were sparse. Conclusion Our meta-analysis supports therapeutic benefits of liraglutide for patients with T1DM mainly for weight loss and insulin dose reduction. Newly diagnosed or C-pos patients do not appear to experience greater weight loss benefits. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial.

Author

Rao, Vishnu P., Kim, Yoon Kook, Ghazi, Anahita, Park, Jean Y., and Munir, Kashif M.

Subjects
TREATMENT of diabetic neuropathies, RESEARCH, PAIN measurement, HEALTH outcome assessment, MAGNETOTHERAPY, RANDOMIZED controlled trials, BLIND experiment, RESEARCH funding, DESCRIPTIVE statistics, FOOT, STATISTICAL sampling, PAIN management, EVALUATION
Abstract

Aims: Transcutaneous magnetic stimulation (TCMS) is successful in decreasing pain in several neurologic conditions. This multicenter parallel double‐blind phase II clinical trial is a follow‐up to a pilot study that demonstrated pain relief in patients with diabetic peripheral neuropathy (DPN) treated with TCMS. Methods: Thirty‐four participants with confirmed DPN and baseline pain score ≥ 5 were randomized to treatment at two sites. Participants were treated with either TCMS (n = 18) or sham (n = 16) applied to each foot once a week for four weeks. Pain scores using the Numeric Pain Rating Scale after 10 steps on a hard floor surface and answers to Patient‐Reported Outcomes Measurement Information System pain questions were recorded by participants daily for 28 days. Results: Thirty‐one participants completed the study and were analyzed. Average pain scores decreased from baseline in both the groups. The difference in pain scores between TCMS and sham treatments was −0.55 for morning, −0.13 for evening, and −0.34 overall, below the pre‐determined clinically relevant difference of −2. Moderate adverse events that resolved spontaneously were experienced in both treatment arms. Conclusion: In this two‐arm trial, TCMS failed to demonstrate a significant benefit over sham in patient reported pain suggesting a substantial placebo effect in our previous pilot study. Trial registration: TCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy, https://clinicaltrials.gov/ct2/show/NCT03596203, ID‐NCT03596203. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Additional file 1 of Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study

Author

Lin, Shu-Man, Liu, Peter Pin-Sung, Tu, Yu-Kang, Lai, Edward Chia-Cheng, Yeh, Jih-I, Hsu, Jin-Yi, Munir, Kashif M., Peng, Carol Chiung-Hui, Huang, Huei-Kai, and Loh, Ching-Hui

Abstract

Additional file 1: Figure S1. Flowchart of patient selection. Table S1. Specification and emulation of a target trial evaluating the effect of NOACs versus warfarin on the risk of incident heart failure using real-world data from Taiwan’s NHIRD. Table S2. Baseline characteristics of elderly patients with atrial fibrillation and diabetes receiving NOAC or warfarin in the original population, without weighting or matching. Table S3. Risk of heart failure in elderly patients with atrial fibrillation and diabetes receiving NOAC versus warfarin in the sensitivity analysis applying propensity score matching and that applying multivariable regression models without propensity score methods. Table S4. Baseline characteristics of elderly patients with atrial fibrillation and diabetes receiving NOAC or warfarin in the population after propensity score matching.

Published
2023
Full Text
View/download PDF

29. 140-LB: Management of Inpatient Hyperglycemia Guided by Continuous Glucose Monitoring (CGM) in Insulin-Treated Patients with Diabetes—A Randomized Clinical Trial

Author

SPANAKIS, ILIAS (ELIAS), primary, URRUTIA, MARIA A., additional, SCIOSCIA, MARIA F., additional, GALINDO, RODOLFO J., additional, VELLANKI, PRIYATHAMA, additional, MIGDAL, ALEXANDRA L., additional, DAVIS, GEORGIA M., additional, IDREES, THAER, additional, PASQUEL, FRANCISCO J., additional, SINGH, LAKSHMI G., additional, GOTHONG, CHIKARA, additional, MARCANO, ISABEL, additional, LIZAMA, SERGIO, additional, MUNIR, KASHIF M., additional, CHESNEY, CATALINA, additional, MAGUIRE, REBECCA D., additional, SCOTT, WILLIAM H., additional, PENG, LIMIN, additional, and UMPIERREZ, GUILLERMO E., additional

Published
2022
Full Text
View/download PDF

32. Reninoma Presenting in Pregnancy

Author

Diker-Cohen, Talia, Abraham, Smita Baid, Rauschecker, Mitra, Papadakis, Georgios Z., Munir, Kashif M., Brown, Eric, Lyssikatos, Charalampos, Belyavskaya, Elena, Merino, Maria, and Stratakis, Constantine A.

Published
2014

43. Risk of developing diabetes in patients with atrial fibrillation taking non‐vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study

Author

Huang, Huei‐Kai, primary, Liu, Peter Pin‐Sung, additional, Lin, Shu‐Man, additional, Hsu, Jin‐Yi, additional, Peng, Carol Chiung‐Hui, additional, Munir, Kashif M., additional, Wu, Ting‐Yu, additional, Yeh, Jih‐I, additional, Loh, Ching‐Hui, additional, and Tu, Yu‐Kang, additional

Published
2020
Full Text
View/download PDF

50. Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-analysis.

Author

Carol Chiung-Hui Peng, Yu-Kang Tu, Gin Yi Lee, Chang, Rachel Huai-En, Yuting Huang, Bukhari, Khulood, Yao-Chou Tsai, Yunting Fu, Huei-Kai Huang, Munir, Kashif M., Peng, Carol Chiung-Hui, Tu, Yu-Kang, Lee, Gin Yi, Huang, Yuting, Tsai, Yao-Chou, Fu, Yunting, and Huang, Huei-Kai

Subjects
PROTON pump inhibitors, GLYCEMIC control, HEMOGLOBINS
Abstract

Context: Whether proton pump inhibitors (PPI) can improve glycemic control among individuals with diabetes or decrease the risk of incident diabetes in the general population is unclear.Objective: To evaluate the impact of PPI therapy on glycemic control among individuals with diabetes and the risk of diabetes among those without diabetes.Results: PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to November 21, 2020. We included studies comparing glycosylated hemoglobin (HbA1c) or fasting blood glucose (FBG) among individuals with diabetes treated with and without PPI therapy as an add-on to standard therapy. Studies evaluating the risk of incident diabetes among individuals taking PPI were assessed. We performed dual independent review, data extraction, and quality assessment. Weighted mean differences between groups or relative risks were imputed using random-effects models.Results: Seven studies (n = 342) for glycemic control and 5 studies (n = 244 439) for risk of incident diabetes were included. Compared with standard therapy, add-on PPI was associated with a significant decrease in HbA1c (WMD, -0.36 %; 95% CI, -0.68 to -0.05; P = 0.025) and FBG (WMD, -10.0 mg/dL; 95% CI, -19.4 to -0.6; P = 0.037). PPI use did not reduce the risk of incident diabetes (pooled RR, 1.10; 95% CI, 0.89 to 1.34; P = 0.385).Conclusion: Add-on PPI improved glycemic indices among individuals with diabetes but did not alter the risk of incident diabetes. The effects of PPI on glycemic control should be considered when prescribing antacids to patients with diabetes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results